PHILADELPHIA–(BUSINESS WIRE)– #ALK–Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer
PHILADELPHIA–(BUSINESS WIRE)– #ALK–Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer